What is William Blair’s Forecast for CVRx FY2025 Earnings?

CVRx, Inc. (NASDAQ:CVRX) – Research analysts at William Blair decreased their FY2025 earnings per share estimates for shares of CVRx in a note issued to investors on Thursday, November 6th. William Blair analyst B. Vazquez now forecasts that the company will post earnings per share of ($2.01) for the year, down from their prior estimate of ($1.98). The consensus estimate for CVRx’s current full-year earnings is ($1.91) per share. William Blair also issued estimates for CVRx’s Q4 2025 earnings at ($0.42) EPS, Q1 2026 earnings at ($0.52) EPS, Q2 2026 earnings at ($0.53) EPS, Q3 2026 earnings at ($0.49) EPS, Q4 2026 earnings at ($0.43) EPS and FY2026 earnings at ($1.97) EPS.

CVRx (NASDAQ:CVRX) last announced its earnings results on Wednesday, November 5th. The company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.01. CVRx had a negative net margin of 95.61% and a negative return on equity of 79.31%. The business had revenue of $14.69 million for the quarter, compared to the consensus estimate of $14.16 million. CVRx has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS.

Other research analysts have also recently issued research reports about the company. Cantor Fitzgerald increased their target price on CVRx from $11.00 to $13.00 and gave the company an “overweight” rating in a research note on Thursday. Canaccord Genuity Group increased their price objective on CVRx from $9.00 to $11.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of CVRx in a research report on Thursday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $13.17.

CVRx Stock Performance

CVRx stock opened at $9.71 on Monday. CVRx has a fifty-two week low of $4.30 and a fifty-two week high of $18.55. The company has a debt-to-equity ratio of 0.85, a quick ratio of 10.78 and a current ratio of 11.99. The stock has a market cap of $253.94 million, a P/E ratio of -4.62 and a beta of 1.28. The firm’s fifty day moving average price is $8.74 and its 200-day moving average price is $7.57.

Hedge Funds Weigh In On CVRx

Institutional investors and hedge funds have recently bought and sold shares of the stock. Lord Abbett & CO. LLC purchased a new position in CVRx during the 1st quarter valued at $4,852,000. Parkman Healthcare Partners LLC boosted its stake in shares of CVRx by 33.5% during the 1st quarter. Parkman Healthcare Partners LLC now owns 1,229,522 shares of the company’s stock valued at $15,037,000 after purchasing an additional 308,348 shares in the last quarter. Balyasny Asset Management L.P. increased its position in shares of CVRx by 65.5% during the second quarter. Balyasny Asset Management L.P. now owns 674,685 shares of the company’s stock valued at $3,967,000 after buying an additional 267,063 shares during the period. Marshall Wace LLP increased its position in shares of CVRx by 238.1% during the second quarter. Marshall Wace LLP now owns 350,080 shares of the company’s stock valued at $2,058,000 after buying an additional 246,548 shares during the period. Finally, FourWorld Capital Management LLC raised its stake in CVRx by 563.7% in the second quarter. FourWorld Capital Management LLC now owns 124,123 shares of the company’s stock worth $730,000 after buying an additional 105,422 shares in the last quarter. 75.27% of the stock is currently owned by institutional investors.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.